Neisseria meningitidis compositions and methods thereof
US-8986710-B2 · Mar 24, 2015 · US
Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9757443B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9757443-B2 |
| Application number | US-201113295030-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 11, 2011 |
| Priority date | Sep 10, 2010 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis , and methods related thereto.
First claim
Opening claim text (preview).
What is claimed is: 1. An immunogenic composition comprising an immunologically effective amount of a first non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 50, wherein the first non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 50 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 2. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 44, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 44 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 3. The immunogenic composition of claim 2 , wherein the first non-pyruvylated non-lipidated polypeptide is encoded by a nucleotide sequence comprising SEQ ID NO: 45. 4. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a non-lipidated N. meningitidis , serogroup B, 2086 Subfamily A polypeptide. 5. The immunogenic composition of claim 4 , wherein the Subfamily A polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 55. 6. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 57, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 57 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 7. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 58, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 58 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 8. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 59, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 59 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 9. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 60, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 60 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 10. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 62, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 62 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry. 11. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide having the amino acid sequence set forth in SEQ ID NO: 64, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 64 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
Immunostimulants · CPC title
- A61K39/095Primary
Neisseria · CPC title
from Neisseriaceae (F) · CPC title
Saponins; Quil A; QS21; ISCOMS · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9757443B2 cover?
- The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseri…
- Who is the assignee on this patent?
- Anderson Annaliesa Sybil, Jansen Kathrin Ute, Ruppen Mark E, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/095. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).